Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $37000.0.

  • Apellis Pharmaceuticals' Non Operating Income fell 4714.29% to $37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year decrease of 5963.04%. This contributed to the annual value of $16.8 million for FY2024, which is 6011.64% down from last year.
  • Apellis Pharmaceuticals' Non Operating Income amounted to $37000.0 in Q3 2025, which was down 4714.29% from $146000.0 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Non Operating Income ranged from a high of $50.3 million in Q4 2022 and a low of -$603000.0 during Q3 2023
  • Moreover, its 5-year median value for Non Operating Income was $37000.0 (2025), whereas its average is $7.8 million.
  • Examining YoY changes over the last 5 years, Apellis Pharmaceuticals' Non Operating Income showed a top increase of 1092857.14% in 2021 and a maximum decrease of 132000.0% in 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' Non Operating Income (Quarter) stood at $37.3 million in 2021, then skyrocketed by 34.71% to $50.3 million in 2022, then fell by 14.36% to $43.0 million in 2023, then tumbled by 60.05% to $17.2 million in 2024, then plummeted by 99.78% to $37000.0 in 2025.
  • Its Non Operating Income stands at $37000.0 for Q3 2025, versus $146000.0 for Q2 2025 and -$165000.0 for Q1 2025.